Search results
Results from the WOW.Com Content Network
This topic reviews the management of hypertriglyceridemia. Other relevant topics include: (See "Hypertriglyceridemia in adults: Approach to evaluation".) (See "Hypertriglyceridemia-induced acute pancreatitis".) (See "Lipoprotein classification, metabolism, and role in atherosclerosis".)
Early clinical recognition of HTG-induced pancreatitis (HTGP) is important to provide appropriate therapy and to prevent further episodes [1,2,4-6]. This topic will review the etiology, clinical features, and management of acute HTGP.
{{configCtrl2.info.metaDescription}}
This topic reviews the relationship between hypertriglyceridemia and adverse cardiovascular events, the mechanisms by which this might occur, the disorders of triglyceride (TG) metabolism that have been identified, and our approach to the management of hypertriglyceridemia.
Treatment goals – The goals of management of patients with hypertriglyceridemia are to lower the risk for pancreatitis and atherosclerotic cardiovascular disease (ASCVD), although evidence on the efficacy of triglyceride (TG) lowering is limited.
Hypertriglyceridemia is the primary lipid abnormality among patients with CKD, although abnormalities in cholesterol and apolipoproteins also occur . This topic reviews the pathogenesis, epidemiology, and treatment of lipid and lipoprotein abnormalities in patients with nondialysis CKD.
The treatment of high cholesterol and/or triglycerides is a lifelong process. Although medications can rapidly lower your levels (within a week), it often takes 6 to 12 months before the effects of lifestyle modifications are noticeable.
- Treatment of pediatric hypercholesterolemia - Overview of statin therapy in pediatric patients
Some people with increased triglyceride levels may need treatment with medication. Lipoprotein(a) — Lipoprotein(a) is a type of low-density lipoprotein. Levels of lipoprotein(a) are largely genetically determined, and high levels are associated with an increased risk of cardiovascular disease.
This effect is most prominent in the nephrotic syndrome, where marked elevations in serum cholesterol and triglycerides often occur. This topic will review the pathogenesis and management of lipid abnormalities in patients with the nephrotic syndrome.